Iluvien® is a tiny, sustained-release implant that delivers a corticosteroid medication called fluocinolone acetonide directly into the eye. It is designed to:
The implant releases medication continuously for up to 36 months, helping to reduce inflammation, decrease swelling, and improve or stabilise vision.
Iluvien® is administered as an intravitreal injection, meaning it is injected directly into the vitreous humor (the gel-like substance inside the eye). The procedure is performed in a clinical setting under sterile conditions. Local anaesthesia is applied to minimise discomfort. The implant is delivered using a specially designed applicator with a fine needle, ensuring precise placement within the eye.
Clinical studies have shown that Iluvien® can lead to sustained improvements in visual acuity and a significant reduction in retinal thickness.
As with any medical procedure, there are potential risks and side effects:
Very common but treatable (more than 1 in 10 people):
Common and usually temporary (up to 1 in 10 people):
Less common but serious (up to 1 in 1,000):
Patients should be monitored regularly for any changes in vision or eye health.
You should use any prescribed eye drops as directed and avoid rubbing your eye. Attend regular eye check-ups to monitor intraocular pressure and implant effectiveness. If you develop sudden pain and persistently blurred vision, please attend your nearest urgent eye care unit.
Patients with the following should not have this treatment:
Other factors to consider before proceeding with treatment:
Always inform your eye specialist about your full medical history before receiving Iluvien®.
Review date: June 2028